REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
46 hedge funds and large institutions have $5.44M invested in REVIVA PHARMA HLDGS INC in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 12 closing their positions.
9,704% more call options, than puts
Call options by funds: $2.25M | Put options by funds: $23K
14.04% more ownership
Funds ownership: 15.73% → 29.77% (+14%)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
4% less funds holding
Funds holding: 48 → 46 (-2)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
22% less capital invested
Capital invested by funds: $6.95M → $5.44M (-$1.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.1M |
| 2 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$1.62M |
| 3 |
HCM
Heights Capital Management
San Francisco,
California
|
+$1.42M |
| 4 |
6CM
683 Capital Management
New York
|
+$779K |
| 5 |
PAP
Persistent Asset Partners
Hong Kong
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$487K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$206K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$191K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$174K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$105K |
RVPH Hedge Fund Activity: Q2 2025 in Review
46 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q2 2025, worth a combined $5.44M — down 22% from $6.95M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RVPH and 11 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 8 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.1M. The largest seller was Tang Capital Management, exiting entirely with an estimated $487K sold.
- 46 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q2 2025, down from 48 in Q1 2025.
- Funds reported $5.44M of REVIVA PHARMA HLDGS INC stock for Q2 2025, down 22% quarter-over-quarter.
- 11 funds opened new REVIVA PHARMA HLDGS INC positions in Q2 2025 and 12 closed out, a net change of -1 holder.
- The largest REVIVA PHARMA HLDGS INC buyer in Q2 2025 was Armistice Capital, an estimated $2.1M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q2 2025 was Tang Capital Management, an estimated $487K sold.
Based on aggregated 13F filings for Q2 2025.